ChemotherapyAdvisor.com Editorial Board Recommends High-Impact Abstracts from the 2013 Gastrointestinal Cancers Symposium

Share this content:
An Exclusive Interview with Steven Cohen, MD
An Exclusive Interview with Steven Cohen, MD

In anticipation of the 2013 Gastrointestinal Cancers Symposium, which begins tomorrow morning in San Francisco, California, Dr. Steven Cohen, MD, has recommended five abstracts that are most significant in terms of clinical impact for the practicing oncologist.

Dr. Cohen is Chief of GI Medical Oncology; Director of the Lung Cancer Section, Division of Hematology/Oncology; Director of the Temple University/Fox Chase hematology/oncology fellowship program; and Chief Medical Officer at Fox Chase Cancer Center Partners, Fox Chase Cancer Center, Philadelphia, PA.


Esophagogastric Cancer

Abstract #LBA4
2:00 PM - 2:10 PM
Cougar-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma
Hugo Ford
Demonstrates that there is a survival benefit for second-line chemotherapy in metastatic esophagogastric cancer
(View our news brief)
 
Abstract #7
2:35 PM - 2:45 PM
Final results of RTOG 0246: A phase II study of selective surgical resection for locoregionally advanced esophageal cancer treated with a paclitaxel-based chemoradiation regimen
Stephen Swisher
Demonstrates the feasibility of a selective surgical approach after definitive chemoradiotherapy for localized esophageal cancer.
(View our news brief)

Pancreatic Cancer

Abstract #LBA148
2:48 PM - 3:00 PM
Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT)

Daniel D. Von Hoff

Important trial demonstrating survival benefit for the addition of nab-paclitaxel to gemcitabine for advanced pancreatic cancer.
(View our news brief)

Colorectal Cancer

Abstract #336
2:00 PM - 2:12 PM
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
Fotios Loupakis
Provocative trial again demonstrating benefit (here PFS) for a 3-chemotherapy backbone in advanced colorectal cancer. Will stimulate much debate over its utility.
(View our news brief)
 
Abstract #337
2:12 PM - 2:24 PM
Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX)
David Cunningham
First randomized trial demonstrating benefit of bevacizumab in elderly patients with CRC.
(View our news brief)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs